SCHEMBL15212398

SCHEMBL15212398

CC1(C(=O)O)Oc2ccc(Nc3nc(Cl)ncc3F)cc2NC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 10/20 0.51
EGFR P00533 6/20 0.48
JAK2 O60674 2/20 0.48
LCK P06239 2/20 0.48
LYN P07948 2/20 0.48
FGFR4 P22455 2/20 0.48
NPC1 O15118 1/20 0.39
JAK1 P23458 3/20 0.39
JAK3 P52333 3/20 0.39
TRPV1 Q8NER1 1/20 0.39
AURKA O14965 2/20 0.36
BMPR1B O00238 1/20 0.36
CDC7 O00311 1/20 0.36
PIK3CD O00329 1/20 0.36
PLK4 O00444 1/20 0.36
STK25 O00506 1/20 0.36
CIT O14578 1/20 0.36
RIOK3 O14730 1/20 0.36
CHEK1 O14757 1/20 0.36
IKBKB O14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2103987 0.87 TRPV1 (0.51) SYKEGFRJAK2LCKLYN
SCHEMBL655687 0.87 SYK (0.64) SYKEGFRJAK2LCKLYN
SCHEMBL656721 0.84 SYK (0.56) SYKEGFRJAK2LCKLYN
SCHEMBL15212360 0.83 SYK (0.49) SYKEGFRJAK2LCKLYN
SCHEMBL15212485 0.83 SYK (0.53) SYKEGFRJAK2LCKLYN
SCHEMBL13007738 0.82 SYK (0.49) SYKEGFRJAK2LCKLYN
SCHEMBL15212509 0.81 SYK (0.47) SYKEGFRJAK2LCKLYN
SCHEMBL16408462 0.81 SYK (0.46) SYKEGFRJAK2LCKLYN
SCHEMBL15212168 0.81 SYK (0.48) SYKEGFRJAK2LCKLYN
SCHEMBL15212505 0.79 SYK (0.46) SYKEGFRJAK2LCKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817306-B1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS MERCK PATENT GMBH (DE) 2015-09-16 EP disclosed
EP-2817306-B1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS MERCK PATENT GMBH (DE) 2015-09-16 EP disclosed
US-9073944-B2 Cyclic diaminopyrimidine derivatives MERCK PATENT GMBH (DE) 2015-07-07 US disclosed
US-9073944-B2 Cyclic diaminopyrimidine derivatives MERCK PATENT GMBH (DE) 2015-07-07 US disclosed
US-9073944-B2 Cyclic diaminopyrimidine derivatives MERCK PATENT GMBH (DE) 2015-07-07 US disclosed
US-20150025066-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025066-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
US-20150025066-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-22 US disclosed
EP-2817306-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES Merck Patent GmbH (DE) 2014-12-31 EP disclosed
WO-2013126132-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed
WO-2013126132-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025066-A1 CYCLIC DIAMINOPYRIMIDINE DERIVATIVES SYK, BTK, LYN SYK 1/4885EGFR 929/4885JAK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.